Boston Scientific (BSX) stock price, revenue, and financials

Boston Scientific market cap is $61.7 b, and annual revenue was $9.91 b in FY 2020

$61.7 B

BSX Mkt cap, 15-Oct-2021

$2.8 B

Boston Scientific Revenue Q1, 2021
Boston Scientific Gross profit (Q1, 2021)1.9 B
Boston Scientific Gross profit margin (Q1, 2021), %67.5%
Boston Scientific Net income (Q1, 2021)341 M
Boston Scientific EBIT (Q1, 2021)370 M
Boston Scientific Cash, 31-Mar-20212 B
Boston Scientific EV68.7 B
Get notified regarding key financial metrics and revenue changes at Boston ScientificLearn more
Banner background

Boston Scientific Revenue

Boston Scientific revenue was $9.91 b in FY, 2020 which is a 7.7% year over year decrease from the previous period.

Embed Graph

Boston Scientific Revenue Breakdown

Embed Graph

Boston Scientific revenue breakdown by business segment: 39.1% from Cardiovascular, 27.8% from Rhythm Management, 30.9% from MedSurg and 2.2% from Other

Boston Scientific revenue breakdown by geographic segment: 57.5% from U.S. and 42.5% from Other Countries

Boston Scientific Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

9.8b10.7b9.9b

Revenue growth, %

9%9%(8%)

Cost of goods sold

2.8b3.1b3.5b

Gross profit

7.0b7.6b6.4b

Gross profit Margin, %

71%71%65%

R&D expense

1.1b1.2b1.1b

General and administrative expense

3.6b3.9b3.8b

Operating expense total

5.5b6.1b6.5b

Depreciation and amortization

599.0m699.0m789.0m

EBIT

1.5b1.5b(80.0m)

EBIT margin, %

15%14%(1%)

Interest expense

241.0m473.0m361.0m

Interest income

3.0m30.0m

Pre tax profit

1.4b687.0m(79.0m)

Income tax expense

(249.0m)(4.0b)2.0m

Net Income

1.7b4.7b(82.0m)

EPS

1.23.3(0.1)

Boston Scientific Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

146.0m217.0m1.7b

Accounts Receivable

1.6b1.8b1.5b

Inventories

1.2b1.6b1.4b

Current Assets

4.0b4.7b6.7b

PP&E

1.8b2.1b2.1b

Goodwill

7.9b10.2b10.0b

Total Assets

21.0b30.6b30.8b

Accounts Payable

349.0m542.0m513.0m

Short-term debt

2.3b1.4b13.0m

Current Liabilities

5.3b4.9b3.7b

Long-term debt

4.8b8.6b9.1b

Total Debt

4.8b10.0b9.1b

Common Stock

16.0m16.0m17.0m

Additional Paid-in Capital

17.3b17.6b19.7b

Retained Earnings

(7.0b)(2.3b)(2.4b)

Total Equity

8.7b13.9b15.3b

Debt to Equity Ratio

0.6 x0.7 x0.6 x

Debt to Assets Ratio

0.2 x0.3 x0.3 x

Financial Leverage

2.4 x2.2 x2 x

Boston Scientific Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

104.0m1.7b4.7b(82.0m)

Depreciation and Amortization

844.0m894.0m1.0b1.1b

Accounts Receivable

(30.0m)(110.0m)(130.0m)335.0m

Inventories

(107.0m)(83.0m)(290.0m)(65.0m)

Accounts Payable

195.0m(631.0m)111.0m88.0m

Cash From Operating Activities

1.4b310.0m1.8b1.5b

Purchases of PP&E

(319.0m)(316.0m)(461.0m)(376.0m)

Cash From Investing Activities

(1.0b)(1.9b)(5.0b)(411.0m)

Short-term Borrowings

1.2b21.0m(1.6b)(2.9b)

Long-term Borrowings

(3.2b)(1.2b)(3.6b)(3.2b)

Dividends Paid

(28.0m)

Cash From Financing Activities

110.0m1.4b3.0b293.0m

Net Change in Cash

1.0b(188.0m)(222.0m)1.4b

Interest Paid

235.0m262.0m449.0m359.0m

Income Taxes Paid

(42.0m)1.0b242.0m207.0m

Quarterly

USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

298.0m853.0m1.3b424.0m578.0m704.0m11.0m341.0m

Depreciation and Amortization

268.0m

Accounts Receivable

(117.0m)

Inventories

(115.0m)

Accounts Payable

(10.0m)

Cash From Operating Activities

193.0m(210.0m)291.0m350.0m642.0m1.1b(77.0m)192.0m835.0m284.0m

Purchases of PP&E

(60.0m)(134.0m)(210.0m)(63.0m)(154.0m)(275.0m)(100.0m)(168.0m)(217.0m)(75.0m)

Cash From Investing Activities

(173.0m)(664.0m)(1.3b)(410.0m)(1.0b)(5.0b)(76.0m)(135.0m)(264.0m)71.0m

Short-term Borrowings

(316.0m)472.0m(403.0m)(630.0m)(325.0m)(987.0m)(1.0b)(2.7b)(2.9b)

Long-term Borrowings

(602.0m)(1.2b)(1.2b)(1.5b)(1.5b)(1.5b)(1.5b)(2.9b)(2.9b)

Dividends Paid

(14.0m)(14.0m)

Cash From Financing Activities

130.0m856.0m1.0b2.1b2.4b3.7b256.0m1.4b1.1b(95.0m)

Net Change in Cash

151.0m(23.0m)(37.0m)2.1b2.0b(153.0m)93.0m1.4b1.7b258.0m

Boston Scientific Ratios

USDFY, 2017

Boston Scientific Operating Metrics

FY, 2018FY, 2019FY, 2020

Countries

130120120

Medical Institutions Covered (U.S.)

35 k37 k35 k

Manufacturing Facilities

161616

Patent Applications

5 k6 k6 k

Patents Issued

19 k21 k18 k

Boston Scientific Human Capital

FY, 2020FY, 2019FY, 2018
Female, percent15.8%23.5%9.3%
Female (Board of Directors), percent10%6%
Male (Supervisors and Managers), percent20%30.9%12.3%
Female (Supervisors and Managers), percent13.3%19.1%7.7%
Male (Board of Directors), percent23.3%14%
Male, percent17.5%26.5%10.7%
Male (Senior Management), percent14.1%
Female (Senior Management), percent5.9%
Male (Executive Officers), percent16.2%
Other3.8%

Ethnicity

FY, 2018
White (USA), percent68.4%
Black / African American (USA), percent6.5%
Hispanic / Latino (USA), percent9.5%
Asian (USA), percent13.4%
Other2.2%

Boston Scientific Employee Rating

4.33095 votes
Culture & Values
4.3
Work/Life Balance
4.1
Senior Management
4.1
Salary & Benefits
4.2
Career Opportunities
4
Source